Posts tagged Non-Small Cell Lung Cancer (NSCLC)
Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers
Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers

Background: National Comprehensive Cancer Network (NCCN) guidelines recommend biomarker testing as the first step in the management of patients with advanced non-small cell lung cancer (aNSCLC). We assessed anaplastic lymphoma kinase (ALK) testing rates and factors related to underuse in community medical systems between 2012 and 2019 to understand guideline adoption. Conclusion: This analysis of real-world data shows increasing test use by year; however, one fifth of patients eligible for ALK testing still remain untested and potentially missing therapeutic options. READ ARTICLE

The Oncologist DOI:doi.org/10.1002/onco.13779

Authors: Eric H. Bernicker,Yan Xiao,Anup Abraham,Baiyu Yang,Denise A. Croix,Stella Redpath,Julia Engstrom-Melnyk,Roma Shah,Jaya Madala,Timothy C. Allen

Read More
Real-World OutcomesKirk SmithNational Comprehensive Cancer Network (NCCN), ALK Testing Guidelines, Non-Small Cell Lung Cancer (NSCLC), U.S. Community Medical Centers
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

Objective: We investigated the prevalence of ALK rearrangements in a Chinese NSCLC population, and correlated clinical outcomes of crizotinib with different ALK partners/variants. Conclusions: This study illustrates the patterns of ALK fusion variants present in Chinese NSCLC patients and might help explain heterogeneous clinical outcomes to crizotinib treatment according to different ALK fusion variants. READ ARTICLE

Targeted Oncology DOI:10.1007/s11523-019-00631-x

Authors: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang

Read More
Real-World OutcomesKirk SmithALK Fusion Variants, Clinical Outcomes, Chinese Patients, Non-Small Cell Lung Cancer (NSCLC), Crizotinib